2′-Fucosyllactose (2′-FL) containing genetic material from a genetically modified E. coli strain was developed by Japan's Kyowa Hakko Bio Co., primarily used as a nutritional substance in infant formula; prolyl oligopeptidase containing genetic material from a genetically modified Trichoderma reesei strain was developed by IFF Australia Pty, mainly used in brewing beverage production; genetically modified soybean MON94637 was developed by Bayer, expressing cry1A.2 and cry1B.2 proteins from a Bacillus thuringiensis strain, with characteristics of resistance to Lepidopteran pests. Previously, this genetically modified soybean had been approved in Canada for food, feed, and cultivation.